Show simple item record

dc.contributor.authorLiu, David V.
dc.contributor.authorYang, Nicole Jie Yeon
dc.contributor.authorWittrup, Karl Dane
dc.date.accessioned2014-11-17T19:52:04Z
dc.date.available2014-11-17T19:52:04Z
dc.date.issued2014-05
dc.date.submitted2014-01
dc.identifier.issn2162-2531
dc.identifier.urihttp://hdl.handle.net/1721.1/91602
dc.description.abstractProtein-based methods of targeted short-interfering RNA (siRNA) delivery have the potential to solve some of the problems faced by nanoparticle-based methods, such as poor pharmacokinetics and biodistribution, low tumor penetration, and polydispersity. However, protein-based targeted delivery has been limited to fusion proteins with polycationic peptides as siRNA carriers, whose high charge density in some cases results in undesirable biophysical and in vivo properties. Here, we present a fully proteinaceous, multiagent approach for targeted siRNA delivery to epidermal growth factor receptor (EGFR), using a nonpolycationic carrier for siRNA. Each agent contributes a fundamentally different mechanism of action that work together for potent targeted RNA interference. The first agent is an EGFR-targeted fusion protein that uses a double-stranded RNA-binding domain as a nonpolycationic siRNA carrier. This double-stranded RNA-binding domain fusion protein can deliver siRNA to the endosomes of an EGFR-expressing cell line. A second agent delivers the cholesterol-dependent cytolysin, perfringolysin O, in a targeted manner, which enhances the endosomal escape of siRNA and induces gene silencing. A third agent that clusters EGFR increases gene-silencing potency and decreases cytolysin toxicity. Altogether, this system is potent, with only 16 nmol/l siRNA required for gene silencing and a therapeutic window that spans two orders of magnitude of targeted cytolysin concentrations.en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (Grant AI065824)en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (Grant CA101830)en_US
dc.language.isoen_US
dc.relation.isversionofhttp://dx.doi.org/10.1038/mtna.2014.14en_US
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported Licenseen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/en_US
dc.sourceMolecular Therapy Nucleic Acidsen_US
dc.titleA Nonpolycationic Fully Proteinaceous Multiagent System for Potent Targeted Delivery of siRNAen_US
dc.typeArticleen_US
dc.identifier.citationLiu, David V, Nicole J Yang, and K Dane Wittrup. “A Nonpolycationic Fully Proteinaceous Multiagent System for Potent Targeted Delivery of siRNA.” Mol Ther Nucleic Acids 3, no. 5 (May 13, 2014): e162. © 2014 The American Society of Gene & Cell Therapyen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biological Engineeringen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Chemical Engineeringen_US
dc.contributor.departmentKoch Institute for Integrative Cancer Research at MITen_US
dc.contributor.mitauthorLiu, David V.en_US
dc.contributor.mitauthorYang, Nicole Jie Yeonen_US
dc.contributor.mitauthorWittrup, Karl Daneen_US
dc.relation.journalMolecular Therapy—Nucleic Acidsen_US
dc.eprint.versionFinal published versionen_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dspace.orderedauthorsLiu, David V; Yang, Nicole J; Wittrup, K Daneen_US
dc.identifier.orcidhttps://orcid.org/0000-0003-2398-5896
dc.identifier.orcidhttps://orcid.org/0000-0002-0882-7761
mit.licensePUBLISHER_CCen_US
mit.metadata.statusComplete


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record